(1 - 30 von 50
)
Context The…utics halting 'noncritical R&D' spending to ...
— Martin Lehr, CEO of Context The…utics. Context The…utics. By John George – Senior Reporter, Philadelphia Business Journal. › news
Lunch with Leaders: Martin Lehr - CHOP Research InstituteChildren's Hospital of Philadelphia
www.research.chop.edu
— Martin Lehr is the co-founder and CEO of Context The…utics. Context The…utics is a Philadelphia-based, clinical-stage ...
Context The…utics CEO charts path for fiscal stability ...Proactive Investors
www.proactiveinvestors.co.uk
... through the execution of the Phase 1b portion of the ELONA trial and the advancement of our CLDN6xCD3 bispecific antibody program,” CEO Martin Lehr said.
Context The…utics CEO charts path for fiscal stability into ...
— ... of our CLDN6xCD3 bispecific antibody program to an Investigational New Drug Application (IND),” CEO Martin Lehr said in a statement. › ...
sortiert nach Relevanz / Datum